RE:Without SalesI have seen biotech stocks with no FDA approved products and only trading on potential of possible approval, trade up to $5 to 10 billion in valuation.
The potential for Poda is ENORMOUS.
There are 1.3 billion smokers each consuming 10 cigarettes per day or 13 billion cigarettes per day.
On a monthly basis that amounts to 390 billion cigarettes per month.
On a yearly basis it amounts to 4.680 trillions cigarettes per year.
Phillipp Morris sold 85 billion sticks in one year out of a possible market of 4.680 trillions sticks.
This market is barely scratched.
Lets have some fun and assume that the world smoked Poda pods, that means a potential yearly revenue of:
4.680 trillion pods per year * .127 cents per pod profit = $ 468 billion per year in profits
So do you really think that at $ 2 per share or $ 284 million valuation that we were overvalued compared to possible potential of $468 billion per year in profits.
Invictus was a loser and invested in the wrong product.
Poda is the future and is invested in the right product and industry.
Sales or no sales, potential alone puts this stock at $ 5 per share, as a speculation price.
Armistice Capital put valuation at $ 2 per share on potential alone, they knew that Poda had no sales.
And Armistice wanted in cheap.
My personal opinion